Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H19N7O2.2ClH |
| Molecular Weight | 438.311 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.COC1=CC=CC(OCCCN)=C1C2=CC(NC3=CN=C(C=N3)C#N)=NN2
InChI
InChIKey=KMEIPKXRCJTZBZ-UHFFFAOYSA-N
InChI=1S/C18H19N7O2.2ClH/c1-26-14-4-2-5-15(27-7-3-6-19)18(14)13-8-16(25-24-13)23-17-11-21-12(9-20)10-22-17;;/h2,4-5,8,10-11H,3,6-7,19H2,1H3,(H2,22,23,24,25);2*1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C18H19N7O2 |
| Molecular Weight | 365.3892 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
LY2606368 (Prexasertib) is a small-molecule Chk-1 inhibitors invented by Array and being developed by Eli Lilly and Company. Lilly is responsible for all clinical development and commercialization activities. LY2606368 is advancing in Phase 2 clinical trials for cancer. Prexasertib preferentially binds to and inhibits CHK1 and, to a lesser extent, inhibits CHK2. Chk-1 is a protein kinase that regulates the tumor cell's response to DNA damage often caused by treatment with chemotherapy. In response to DNA damage, Chk-1 blocks cell cycle progression in order to allow for repair of damaged DNA, thereby limiting the efficacy of chemotherapeutic agents. Inhibiting Chk-1 in combination with chemotherapy can enhance tumor cell death by preventing these cells from recovering from DNA damage.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4630 |
0.9 nM [Ki] | ||
Target ID: CHEMBL2527 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
105 mg/m2 IV once every 14 days of a 28 day cycle
Route of Administration:
Intravenous
In a functional assay, LY2606368 (PREXASERTIB) potently abrogated the G2–M checkpoint activated by doxorubicin in p53-deficient HeLa cells with an EC50 of 9 nmol/L. LY2606368 did inhibit DNA damage-induced CHK2 autophosphorylation with an IC50 of less than 31 nmol/L. 100 nmol/L LY2606368 did not inhibit PMA-stimulated RSK but instead weakly stimulated phosphorylation of S6 on serines 235/236. LY2606368 was broadly antiproliferative with IC50 values typically <50 nmol/L in the most sensitive cell lines with a minority of cell lines showing considerable resistance with IC50's >1,000 nmol/L
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:04:37 GMT 2023
by
admin
on
Sat Dec 16 11:04:37 GMT 2023
|
| Record UNII |
9RFT476U2L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1234015-54-3
Created by
admin on Sat Dec 16 11:04:37 GMT 2023 , Edited by admin on Sat Dec 16 11:04:37 GMT 2023
|
PRIMARY | |||
|
9RFT476U2L
Created by
admin on Sat Dec 16 11:04:37 GMT 2023 , Edited by admin on Sat Dec 16 11:04:37 GMT 2023
|
PRIMARY | |||
|
46700755
Created by
admin on Sat Dec 16 11:04:37 GMT 2023 , Edited by admin on Sat Dec 16 11:04:37 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|